Notícias

The U.S. Federal Trade Commission sued Hims & Hers on Wednesday alleging the telehealth platform shared ‌users' health data with online advertisers, despite promising privacy, and engaged ‌in deceptive billing and cancellation practices. Hims & Hers stock added to losses after ‌the news and was ⁠trading down around 12%. ⁠The company offers telehealth appointments and prescriptions for erectile dysfunction, hair loss, and mental health medications, which it ships straight to customers.

BlackRock disclosed ownership of 26.5 million HIMS shares, representing a stake of about 12%.

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.32, indicating a -3.04% shift from the previous trading day.

An FDA advisory panel backed six of seven peptides for possible inclusion on the 503A compounding list, with Emideltide the only rejection.

Joe Spector helped build a multibillion-dollar telehealth company. Now he’s on to own remote vet services.

Hims & Hers Health Inc. is in the spotlight Friday after an FDA advisory panel voted Thursday to recommend four key peptides be added to a federal list that would allow compounding pharmacies to legally produce them. FDA Panel Splits,...

A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million

Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the news means for HIMS stock.

Hims & Hers Health stock has delivered a very large 5 year gain, yet the latest valuation work suggests the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and supporting market multiples. Over 5 years, Hims & Hers Health has returned 312.9%, which puts the current debate squarely on whether earlier investors have already captured most of the value or if the rerating still has room to run. The outcome of the recent FDA peptide...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Earlier in July 2026, Hims & Hers Health announced that Chief Accounting Officer and Principal Accounting Officer Irene Becklund will resign effective October 9, 2026, with CFO Yemi Okupe temporarily assuming her responsibilities while the company searches for a permanent successor. Her departure coincides with an FDA advisory panel’s recommendation to ease compounding restrictions on peptides such as BPC-157, an area where Hims & Hers has been building capabilities through its own...

Leerink sees a $2.2 billion peptide market, with Hims potentially capturing about 20%.

Hims & Hers Health (HIMS) is back in focus after an FDA advisory panel recommended allowing broader compounding of peptide BPC-157, a development tied directly to treatments offered through the company’s telehealth platform. See our latest analysis for Hims & Hers Health. Hims & Hers Health shares have been volatile over the past year, with a recent 3.35% 1 day share price gain following the FDA panel news set against a 1 year total shareholder return decline of 42.88%. The 3 year total...

The company gets most of its revenue from branded GLP-1s and other products. Most analysts see the stock fully valued.

The company gets most of its revenue from branded GLP-1s and other products. Most analysts see the stock fully valued.

Hims stock bounded higher Thursday after an FDA panel recommended compounding a popular peptide used in injury recovery.

An FDA advisory panel on Thursday recommended adding the peptide BPC-157 to a list that would allow compounding pharmacies to prepare it more freely for patients.

Quest Diagnostics put up a definitive beat Thursday, driven by solid demand across its consumer division, leading the stock to surge.

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.68, moving 3.21% from the previous trading session.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

The new panelists bring expertise in neurology, pain, dermatology, gastroenterology, addiction, cancer pharmacology and patient advocacy.

The next major catalyst is the FDA’s July 23-24 advisory committee meeting, where regulators will consider whether seven peptides should be added to the Section 503A Bulks List.

Hims & Hers Health trades at $33.39 per share and has stayed right on track with the overall market, gaining 9.6% over the last six months. At the same time, the S&P 500 has returned 11.4%.

A cash-secured put on Hims & Hers stock is one way to potentially buy the stock for a discount or achieve a healthy return.

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.15, moving +2.24% from the previous trading session.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

An FDA advisory committee will review seven peptides for possible inclusion on the Section 503A Bulks List on July 23-24.

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $36.17, moving 5.51% from the previous trading session.

Hims & Hers Health has delivered a very large 3 year return, yet the stock still screens as undervalued on market multiples while only scoring weakly on broader valuation checks. A roughly 344.6% return over 3 years puts Hims & Hers Health among the stronger performers in digital health, which raises the bar for what future growth and execution need to justify. Recent traction in branded GLP-1 and peptide related offerings can support optimistic revenue expectations, but evolving FDA...